Profile data is unavailable for this security.
About the company
SMS Pharmaceuticals Limited is an India-based pharmaceutical manufacturing company. The Company is engaged in the business of manufacturing active pharma ingredients and their intermediates. Its product categories include anti-ulcer, anti-inflammatory, anti-migraine, ant-diabetic, anti-coagulant, anti-viral, anti-retroviral, anti-psychotic, and others. The Company products include ranitidine, famotidine, pantoprazole sodium, itraconazole, lanoconazole, luliconazole, ibuprofen, Dex ibuprofen, fenoprofen calcium, sumatriptan, almotriptan, zolmitriptan, rizatriptan, Ele triptan, vildagliptin, sitagliptin, rosiglitazone, empagliflozin, dapagliflozin, tenofovir, dolutegravir, raltegravir, lamivudine, efavirenz, apixaban, rivaroxaban, levetiracetam, perampanel, lamotrigine, penciclovir, valaciclovir, and others. The Company has manufacturing facilities at Bachupally, Hyderabad, Telangana and also at Kandivalasa Village, Poosapatirega Mandal, Vijayanagaram District, Andhra Pradesh.
- Revenue in INR (TTM)8.97bn
- Net income in INR895.91m
- Incorporated1987
- Employees1.47k
- LocationSMS Pharmaceuticals LtdPlot No.72,H. No.8-2-334/3 & 4 Road No.5, Opp. SBIHYDERABAD 500034IndiaIND
- Phone+91 4 066288888
- Fax+91 4 023551401
- Websitehttps://smspharma.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Morepen Laboratories Ltd | 17.87bn | 994.48m | 22.25bn | 1.81k | 22.37 | -- | 15.10 | 1.25 | 1.81 | 1.81 | 32.65 | -- | -- | -- | -- | 9,850,214.00 | -- | 8.14 | -- | 12.81 | 33.71 | 31.83 | 5.61 | 5.91 | -- | 5.59 | -- | -- | 7.17 | 16.26 | 22.73 | 28.58 | 65.86 | -- |
| Unichem Laboratories Ltd | 22.14bn | 2.95bn | 22.26bn | 3.33k | 7.57 | -- | 5.31 | 1.01 | 41.79 | 41.79 | 314.32 | -- | -- | -- | -- | 6,654,374.00 | -- | -0.5598 | -- | -0.6977 | 54.06 | 55.09 | 13.32 | -1.18 | -- | 3.47 | -- | -- | 18.25 | 13.85 | 246.67 | -- | -18.68 | -- |
| Bliss GVS Pharma Ltd | 8.68bn | 1.09bn | 22.81bn | 966.00 | 21.18 | -- | 15.49 | 2.63 | 10.18 | 10.18 | 80.97 | -- | -- | -- | -- | 8,986,598.00 | -- | 6.04 | -- | 7.54 | 52.65 | 46.33 | 13.18 | 9.45 | -- | 8.44 | -- | 8.27 | 5.13 | 3.27 | 11.72 | -2.82 | 5.18 | 0.00 |
| Hikal Ltd | 17.46bn | -130.00m | 22.97bn | 2.06k | -- | -- | 15.68 | 1.32 | -1.05 | -1.05 | 141.83 | -- | -- | -- | -- | 8,465,567.00 | -- | 4.78 | -- | 7.00 | 55.47 | 48.00 | -0.7447 | 5.71 | -- | 1.21 | -- | 14.83 | 4.21 | 4.29 | 30.46 | 1.46 | -2.77 | 3.13 |
| Dishman Carbogen Amcis Ltd | 27.97bn | 1.19bn | 25.71bn | 1.11k | 21.65 | -- | 5.74 | 0.9194 | 7.57 | 7.57 | 178.50 | -- | -- | -- | -- | 25,287,880.00 | -- | -0.7247 | -- | -0.9005 | 84.96 | 74.27 | 4.25 | -2.77 | -- | 1.31 | -- | -- | 3.66 | 5.82 | 102.11 | -54.07 | -11.91 | -- |
| Gufic BioSciences Ltd | 8.97bn | 500.38m | 27.43bn | 1.99k | 54.83 | -- | 33.84 | 3.06 | 4.99 | 4.99 | 89.42 | -- | -- | -- | -- | 4,513,114.00 | -- | 10.27 | -- | 16.11 | 55.87 | 46.41 | 5.58 | 10.48 | -- | 2.73 | -- | 1.31 | 1.63 | 16.69 | -19.14 | 25.15 | 13.64 | 14.87 |
| Orchid Pharma Ltd | 8.11bn | 188.68m | 28.67bn | 737.00 | 152.02 | -- | 54.28 | 3.53 | 3.72 | 3.72 | 160.07 | -- | -- | -- | -- | 11,006,770.00 | -- | 1.40 | -- | 1.72 | 36.82 | 35.89 | 2.14 | 2.75 | -- | 0.4822 | -- | -- | 12.48 | 13.76 | 8.13 | -- | 104.06 | -- |
| RPG Life Sciences Ltd | 6.74bn | 2.03bn | 29.83bn | 1.33k | 14.72 | -- | 13.34 | 4.43 | 122.51 | 122.51 | 407.37 | -- | -- | -- | -- | 5,061,758.00 | -- | 21.05 | -- | 27.78 | 64.34 | 63.28 | 30.07 | 16.68 | -- | 174.47 | -- | 24.92 | 12.26 | 11.71 | 109.03 | 44.58 | 27.39 | 37.97 |
| Gujarat Themis Biosyn Ltd | 1.59bn | 477.88m | 31.31bn | 221.00 | 65.51 | -- | 54.08 | 19.65 | 4.39 | 4.39 | 14.62 | -- | -- | -- | -- | 7,209,322.00 | -- | 30.70 | -- | 34.37 | 62.78 | 68.03 | 29.99 | 35.51 | -- | 55.73 | -- | -- | -11.20 | 12.12 | -17.56 | 15.55 | 104.61 | 24.95 |
| Aarti Drugs Ltd | 25.22bn | 2.03bn | 32.90bn | 1.28k | 16.33 | -- | 12.36 | 1.30 | 22.07 | 22.07 | 274.99 | -- | -- | -- | -- | 19,639,960.00 | -- | 9.09 | -- | 14.39 | 36.35 | 22.09 | 8.03 | 8.08 | -- | 7.00 | -- | 6.07 | -5.60 | 5.74 | -1.90 | 3.53 | 29.85 | 14.87 |
| Senores Pharmaceuticals Ltd | 5.89bn | 1.02bn | 34.41bn | 194.00 | 33.35 | -- | 26.47 | 5.85 | 22.41 | 22.41 | 130.31 | -- | -- | -- | -- | 30,336,080.00 | -- | -- | -- | -- | 58.73 | -- | 17.48 | -- | -- | 5.94 | -- | -- | 85.64 | -- | 86.17 | -- | -- | -- |
| SMS Pharmaceuticals Ltd | 8.97bn | 895.91m | 35.07bn | 1.47k | 36.97 | -- | 27.93 | 3.91 | 10.13 | 10.13 | 101.51 | -- | -- | -- | -- | 6,102,851.00 | -- | 5.58 | -- | 7.66 | 32.55 | 33.78 | 9.71 | 8.05 | -- | 5.85 | -- | 5.72 | 10.36 | 13.70 | 38.75 | 16.97 | 23.62 | 9.86 |
| Innova Captab Ltd | 14.97bn | 1.32bn | 37.03bn | 1.95k | 27.97 | -- | 21.04 | 2.47 | 23.13 | 23.13 | 261.52 | -- | -- | -- | -- | 7,676,703.00 | -- | 10.02 | -- | 15.00 | 36.26 | 27.20 | 8.85 | 8.72 | -- | 12.45 | -- | -- | 15.02 | 27.21 | 35.95 | 35.69 | 109.94 | -- |
| Sun Pharma Advanced Research Co Ltd | 531.36m | -2.68bn | 40.07bn | 316.00 | -- | -- | -- | 75.41 | -8.26 | -8.26 | 1.64 | -- | -- | -- | -- | 1,681,519.00 | -- | -60.53 | -- | -129.98 | -4.34 | -3.83 | -504.20 | -168.34 | -- | -8.82 | -- | -- | -5.00 | -1.35 | 11.55 | -- | -28.16 | -- |
| Zota Health Care Ltd | 4.73bn | -726.58m | 41.87bn | 519.00 | -- | -- | -- | 8.86 | -23.98 | -23.98 | 157.24 | -- | -- | -- | -- | 9,108,992.00 | -- | -7.79 | -- | -10.57 | 57.22 | 42.02 | -15.34 | -8.01 | -- | -3.71 | -- | -- | 62.32 | 25.23 | -293.08 | -- | 49.40 | 0.00 |
Data as of Mar 05 2026. Currency figures normalised to SMS Pharmaceuticals Ltd's reporting currency: Indian Rupee INR
2.96%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| quant Money Managers Ltd.as of 30 Jan 2026 | 2.77m | 2.96% |
| Motilal Oswal Asset Management Co. Ltd.as of 31 Jan 2026 | 915.00 | 0.00% |
| American Century Investment Management, Inc.as of 05 Feb 2026 | 881.00 | 0.00% |
| Bandhan AMC Ltd.as of 31 Jan 2026 | 358.00 | 0.00% |
More ▼
Data from 31 Dec 2025 - 15 Feb 2026Source: FactSet Research Systems Inc.
